Two Sigma Investments
ELVN icon

Two Sigma Investments’s Enliven Therapeutics ELVN Stock Holding History

Two Sigma Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,620
Closed -$329K – 3275
2024
Q4 		$329K Sell
14,620
-7,460
-34% -$193K ﹤0.01% 2709
2024
Q3 		$564K Buy
22,080
+4,843
+28% +$112K ﹤0.01% 2413
2024
Q2 		$403K Buy
+17,237
New +$363K ﹤0.01% 2463
2022
Q3 		– Sell
-29,784
Closed -$145K – 2558
2022
Q2 		$145K Sell
29,784
-31,252
-51% -$153K ﹤0.01% 2221
2022
Q1 		$459K Sell
61,036
-4,515
-7% -$29.8K ﹤0.01% 2060
2021
Q4 		$590K Buy
65,551
+3,177
+5% +$41.7K ﹤0.01% 3086
2021
Q3 		$1.02M Buy
+62,374
New +$1.3M ﹤0.01% 2601
2021
Q2 		– Sell
-12,732
Closed -$430K – 4166
2021
Q1 		$430K Buy
+12,732
New +$647K ﹤0.01% 3068

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Two Sigma Investments's ELVN Position: Q1 2025 in Review

Two Sigma Investments sold out of Enliven Therapeutics (ELVN) in Q1 2025, closing a stake of 14,620 shares — an estimated $329K sold.

Two Sigma Investments first reported a position in ELVN in Q1 2021 and held it in 8 quarters. The position peaked at $1.02M in Q3 2021. 121 funds tracked by Wall St. Rank hold ELVN as of Q1 2025.

  • Two Sigma Investments reported no remaining Enliven Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Investments sold 14,620 Enliven Therapeutics shares in Q1 2025, an estimated $329K.
  • Two Sigma Investments first reported a position in Enliven Therapeutics in Q1 2021 and held it in 8 quarters.
  • Two Sigma Investments's Enliven Therapeutics position peaked at $1.02M in Q3 2021.
  • 121 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2025.

Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.